WFRF:(Lesch M.)
Sökning: WFRF:(Lesch M.) > Efficacy and safety...
- 20 av 31
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04927naa a2200793 4500 | |
| 001 | oai:gup.ub.gu.se/269370 | |
| 003 | SwePub | |
| 008 | 240528s2018 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/2693702 URI |
| 024 | 7 | a https://doi.org/10.1111/adb.126452 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a van den Brink, W.4 aut |
| 245 | 1 0 | a Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level |
| 264 | c 2018-07-17 | |
| 264 | 1 | b Wiley,c 2018 |
| 520 | a Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol-dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90000 alcohol-dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al. 2018). A promising new medication for this population is sodium oxybate, a compound that acts on GABA(B) receptors and extrasynaptic GABA(A) receptors resulting in alcohol-mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new-as yet unpublished-large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO-defined DRLs and (d) from multiple meta-analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol-dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25years. Sodium oxybate is the sodium salt of gamma-hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL. | |
| 650 | 7 | a NATURVETENSKAPx Biologix Biokemi och molekylärbiologi0 (SwePub)106022 hsv//swe |
| 650 | 7 | a NATURAL SCIENCESx Biological Sciencesx Biochemistry and Molecular Biology0 (SwePub)106022 hsv//eng |
| 653 | a acamprosate | |
| 653 | a nalrexone | |
| 653 | a nalmefene | |
| 653 | a heavy drinking | |
| 653 | a alcohol dependence | |
| 653 | a alcoholism | |
| 653 | a drinking risk | |
| 653 | a gamma-hydroxybutyric acid | |
| 653 | a total intravenous anesthesia | |
| 653 | a base-line | |
| 653 | a trajectories | |
| 653 | a as-needed nalmefene | |
| 653 | a withdrawal syndrome | |
| 653 | a use disorders | |
| 653 | a double-blind | |
| 653 | a medications development | |
| 653 | a relapse prevention | |
| 653 | a heavy | |
| 653 | a drinking | |
| 653 | a Biochemistry & Molecular Biology | |
| 653 | a Substance Abuse | |
| 653 | a ates of america | |
| 653 | a v109 | |
| 653 | a p13404 | |
| 700 | 1 | a Addolorato, G.4 aut |
| 700 | 1 | a Aubin, H. J.4 aut |
| 700 | 1 | a Benyamina, A.4 aut |
| 700 | 1 | a Caputo, F.4 aut |
| 700 | 1 | a Dematteis, M.4 aut |
| 700 | 1 | a Gual, A.4 aut |
| 700 | 1 | a Lesch, O. M.4 aut |
| 700 | 1 | a Mann, K.4 aut |
| 700 | 1 | a Maremmani, I.4 aut |
| 700 | 1 | a Nutt, D.4 aut |
| 700 | 1 | a Paille, F.4 aut |
| 700 | 1 | a Perney, P.4 aut |
| 700 | 1 | a Rehm, J.4 aut |
| 700 | 1 | a Reynaud, M.4 aut |
| 700 | 1 | a Simon, N.4 aut |
| 700 | 1 | a Söderpalm, Bo,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology4 aut0 (Swepub:gu)xsodeb |
| 700 | 1 | a Sommer, W. H.4 aut |
| 700 | 1 | a Walter, H.4 aut |
| 700 | 1 | a Spanagel, R.4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi4 org |
| 773 | 0 | t Addiction Biologyd : Wileyg 23:4, s. 969-986q 23:4<969-986x 1355-6215x 1369-1600 |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/269370 |
| 856 | 4 8 | u https://doi.org/10.1111/adb.12645 |
- 20 av 31
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- van den Brink, W ...
- Addolorato, G.
- Aubin, H. J.
- Benyamina, A.
- Caputo, F.
- Dematteis, M.
- visa fler...
- Gual, A.
- Lesch, O. M.
- Mann, K.
- Maremmani, I.
- Nutt, D.
- Paille, F.
- Perney, P.
- Rehm, J.
- Reynaud, M.
- Simon, N.
- Söderpalm, Bo, 1 ...
- Sommer, W. H.
- Walter, H.
- Spanagel, R.
- visa färre...
- Om ämnet
-
- NATURVETENSKAP
- NATURVETENSKAP
- och Biologi
- och Biokemi och mole ...
- Artiklar i publikationen
- Addiction Biolog ...
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
